Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- EXEL Earnings this Week: How Will it Perform?
- Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics
- Buy Rating Affirmed for Exelixis: Promising Phase 3 Trial Results and Favorable Valuation Despite Safety Concerns
- Apple, MARA, Exelixis, Strategy, Dell: Trending by Analysts
- Midday Fly By: GM, Coca-Cola report Q3 beats